glp-1 c elegans DIV-1/PolA2 Promotes GLP-1/Notch-Mediated Cellular Events in Caenorhabditis Analysis of the C. elegans

Kentish JC, McCloskey DT, Layland J, Palmer S, Leiden JM, Martin AF, Solaro RJ (2001) Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventricular muscle

Nausea and vomiting, common side effects of GLP-1 therapy, can lead to volume depletion, further straining kidney function when paired with medications that inhibit the renin-angiotensin system (RAAS)

Employers offering weight-loss coverage rose in 2026 from 17% in 2024 Canadian employers are broadening access to glucagon-like peptide-1 (GLP-1) drugs for weight loss, with the share offering that coverage rising to 37 percent in 2026 from 17 percent in 2024

Continue to drink clear fluids up to 3 hours prior to your procedure

FDA Drug Approval Decisions Expected in April 2026